SCHEMBL176064

SCHEMBL176064

O=C(Cc1ccc(O)cc1)C(O)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.59
FNTB P49356 1/20 0.59
SLC6A2 P23975 1/20 0.58
TRPV1 Q8NER1 2/20 0.51
CA2 P00918 2/20 0.50
CAMK2A Q9UQM7 1/20 0.50
SLC7A5 Q01650 1/20 0.47
POLB P06746 1/20 0.44
CYP1A2 P05177 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
AKR1B1 P15121 1/20 0.44
MME P08473 1/20 0.43
SOAT2 O75908 1/20 0.43
SOAT1 P35610 1/20 0.43
CHRNA1 P02708 1/20 0.42
CHRNG P07510 1/20 0.42
CHRNB1 P11230 1/20 0.42
CHRND Q07001 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16431461 1.00 FNTA (0.59) FNTAFNTBSLC6A2TRPV1CA2
SCHEMBL13960330 0.95 SLC6A2 (0.54) FNTAFNTBSLC6A2TRPV1CA2
SCHEMBL450960 0.93 SLC6A2 (0.56) FNTAFNTBSLC6A2CA2CAMK2A
SCHEMBL454095 0.91 CES2 (0.52) SLC6A2SLC7A5CYP1A2CES2CES1
SCHEMBL10133100 0.86 LMNA (0.56) MME
SCHEMBL30874367 0.81 SLC7A5 (0.64) FNTAFNTBCA2CAMK2ASLC7A5
SCHEMBL107523 0.80 ESR1 (0.49) FNTAFNTBSLC6A2TRPV1CA2
SCHEMBL19566348 0.79 FNTA (0.54) FNTAFNTBTRPV1CA2CAMK2A
SCHEMBL109575 0.78 CYP1A2 (0.50) SLC7A5POLBCYP1A2CES2CES1
SCHEMBL8919717 0.78 CYP1A2 (0.50) SLC7A5POLBCYP1A2CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
US-11821047-B2 High pressure zone formation for pretreatment Apalta Patent OÜ (EE) 2023-11-21 US disclosed
US-20230295678-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2023-09-21 US disclosed
EP-4098750-A1 RAPID PRETREATMENT Sweetwater Energy, Inc. (US) 2022-12-07 EP disclosed
EP-3230463-B1 RAPID PRETREATMENT SWEETWATER ENERGY INC (US) 2022-05-25 EP disclosed
US-11332723-B2 Engineered microorganisms for production of commodity chemicals and cellular biomass THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-05-17 US disclosed
CN-107208120-B Rapid pretreatment 斯威特沃特能源公司 2021-11-23 CN disclosed
US-20210040524-A1 RAPID PRETREATMENT APALTA TEHNOLOOGIA OÜ (EE) 2021-02-11 US disclosed
US-20100086981-A1 COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS QTEROS, INC. (US) 2010-04-08 US disclosed
US-20090203089-A1 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-13 US disclosed
WO-2009097346-A2 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-06 WO disclosed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA FNTA 1376/4885FNTB 852/4885SLC6A2 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.